

## 1 **Classification of Omicron BA.1, BA.1.1 and BA.2 sublineages by** 2 **TaqMan assay consistent with whole genome analysis data**

3  
4 Yosuke Hirotsu<sup>a\*</sup>, Makoto Maejima<sup>b</sup>, Masahiro Shibusawa<sup>b</sup>, Yume Natori<sup>b</sup>, Yuki Nagakubo<sup>b,c</sup>,  
5 Kazuhiro Hosaka<sup>b</sup>, Hitomi Sueki<sup>b</sup>, Hitoshi Mochizuki<sup>a,d,e</sup>, Toshiharu Tsutsui<sup>f</sup>, Yumiko Kakizaki<sup>f</sup>,  
6 Yoshihiro Miyashita<sup>f</sup>, and Masao Omata<sup>e,h</sup>

7  
8 <sup>a</sup>Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi,  
9 Japan<sup>b</sup>Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1  
10 Fujimi, Kofu, Yamanashi, Japan

11 <sup>c</sup>Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu,  
12 Yamanashi, Japan

13 <sup>d</sup>Central Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi,  
14 Japan

15 <sup>e</sup>Department of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu,  
16 Yamanashi, Japan

17 <sup>f</sup>Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi,  
18 Kofu, Yamanashi, Japan

19 <sup>h</sup>The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan

20  
21 \*Corresponding author: Yosuke Hirotsu, Genome Analysis Center, Yamanashi Central  
22 Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan

23 Post code: 400-8506

24 Email: [hirotsu-bdyu@ych.pref.yamanashi.jp](mailto:hirotsu-bdyu@ych.pref.yamanashi.jp)

25 Tel: +81-55-253-7111, Fax: +81-55-253-8011

26 ORCID iD: 0000-0002-8002-834X

27  
28 Running title: TaqMan assay discriminates Omicron sublineages

## 30 **Abstract**

### 31 **Objective**

32 Recently, the Omicron strain of severe acute respiratory syndrome coronavirus 2  
33 (SARS-CoV-2) has spread and replaced the previously dominant Delta strain. Several  
34 Omicron sublineages (BA.1, BA.1.1 and BA.2) have been identified, with in vitro and  
35 preclinical reports showing that the pathogenicity and therapeutic efficacy differs between  
36 BA.1 and BA.2. We sought to develop a TaqMan assay to identify these subvariants.

### 37 **Methods**

38 A TaqMan assay was constructed for rapid identification and genotyping of Omicron  
39 sublineages. We analyzed three characteristic mutations of the spike gene,  $\Delta 69-70$ , G339D  
40 and Q493R, by TaqMan assay. The accuracy of the TaqMan assay was examined by  
41 comparing its results with the results of whole genome sequencing (WGS) analysis.

### 42 **Results**

43 A total of 169 SARS-CoV-2 positive samples were analyzed by WGS and TaqMan  
44 assay. The 127 samples determined as BA.1/BA.1.1 by WGS were all positive for  $\Delta 69-70$ ,  
45 G339D and Q493R by TaqMan assay. Forty-two samples determined as BA.2 by WGS were  
46 negative for  $\Delta 69-70$  but positive for G339D and Q493R by TaqMan. The concordance rate  
47 between WGS and the TaqMan assay was 100% (169/169).

### 48 **Conclusion**

49 TaqMan assays targeting characteristic mutations are useful for identification and  
50 discrimination of Omicron sublineages.

51

52 **Keywords:** SARS-CoV-2, VOC, Omicron, BA.1, BA.2

53

## 54 Introduction

55 The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-  
56 2) has become a threat to human life. However, since its outbreak, scientific knowledge has  
57 accumulated on the transmission and pathogenicity of this virus. Additionally, the  
58 development of vaccines and antiviral treatments has contributed to preventing infection and  
59 reduced the risk of severe illness and mortality.

60 SARS-CoV-2 is an RNA virus with a genome size of approximately 30 kb [1]. SARS-  
61 CoV-2 mutates at a rate of approximately two mutations per month [2], and is prone to  
62 mutations most frequently occurring in the *spike* and *orf1ab* genes [3]. These mutations can  
63 affect transmissibility of the virus and efficacy of antiviral drugs and vaccines. To control the  
64 emergence of new strains, it is important to continuously monitor viral evolution through  
65 genomic epidemiological analysis [4].

66 Recently, a new strain designated B.1.1.529 was detected and isolated in Gauteng  
67 Province, South Africa [5]. The World Health Organization designated the B.1.1.529 lineage  
68 as a variant of concern (VOC) on November 26, 2021 [5], naming it Omicron in line with the  
69 naming convention adopted for previous VOCs using the Greek alphabet, and it has since  
70 spread to a number of countries to become a globally dominant strain [6]. Omicron contains  
71 more than 30 nonsynonymous mutations in the spike protein, therefore Omicron viruses may  
72 reduce the efficacy of antibody therapy and evade vaccine-induced immunity.

73 Omicron viruses are classified into several sublineages including BA.1, BA.1.1,  
74 BA.2 and BA.3, which have been observed worldwide. In the early period following Omicron  
75 emergence, BA.1 was the dominant sublineage; however in Denmark, the United Kingdom,  
76 India, the Philippines, and South Africa, BA.2 became dominant [7-9], with BA.2 reported to  
77 be more transmissible than BA.1 [10]. Convalescent sera and sera from mRNA vaccine  
78 recipients showed decreased neutralizing activity against BA.1, BA.1.1. and BA.2 [11-13]. In  
79 infection experiments using hamsters, BA.2 caused more inflammation in the lungs and was  
80 more pathogenic than BA.1 [8]. Antibody cocktail therapy (casirivimab-imdevimab), which  
81 had lost neutralizing activity in BA.1 and BA.1.1, showed partially neutralizing activity in BA.2  
82 [14]. In addition, S309 (sotrovimab) demonstrated less neutralization activity against BA.2  
83 compared with BA.1 and BA.1.1 [14, 15]. The RNA-dependent RNA polymerase inhibitors,  
84 remdesivir and molnupiravir, and the protease inhibitor nirmatrelvir remained effective in BA.2  
85 as well as BA.1 [14]. Therefore, genotyping of Omicron sublineages is important for  
86 determining infection control and treatment strategies.

87 In this study, we present a TaqMan assay to discriminate between BA.1/BA.1.1 and  
88 BA.2. This method is feasible for any laboratory equipped to perform quantitative real-time  
89 PCR.

90

## 91 **Methods**

### 92 ***SARS-CoV-2 diagnostic testing***

93 Nasopharyngeal swab samples were collected using cotton swabs and placed in  
94 viral transport media (Copan Diagnostics, Murrieta, CA). Multiple molecular diagnostic testing  
95 platforms, including SARS-CoV-2 quantitative reverse transcriptase PCR in accordance with  
96 the protocol developed by the National Institute of Infectious Diseases in Japan [16],  
97 FilmArray Respiratory Panel 2.1 with the FilmArray Torch system (bioMérieux, Marcy-l'Etoile,  
98 France) [17], Xpert Xpress SARS-CoV-2 test using Cepheid GeneXpert (Cepheid, Sunnyvale,  
99 CA) [18] and Lumipulse antigen test with the LUMIPULSE G600II system (Fujirebio, Inc.,  
100 Tokyo, Japan) were used for this study [19, 20].

101

### 102 ***Whole genome sequencing (WGS)***

103 We subjected 171 samples collected from coronavirus disease 2019 (COVID-19)  
104 patients to whole genome analysis (Table S1). WGS analysis was performed as previously  
105 described [21-23]. In brief, SARS-CoV-2 genomic RNA was reverse transcribed into cDNA  
106 and amplified by using the Ion AmpliSeq SARS-CoV-2 Insight Research Assay (Thermo  
107 Fisher Scientific, Waltham MA) on the Ion Torrent Genexus System. Sequencing reads and  
108 quality were processed using Genexus software with SARS-CoV-2 plugins. The  
109 sequencing reads were mapped and aligned using the torrent mapping alignment program.  
110 Assembly was performed with the Iterative Refinement Meta-Assembler [24].

111 To determine the viral clade and lineage classifications, the consensus FASTA files  
112 were downloaded and processed through Nextstrain [25], and Phylogenetic Assignment of  
113 Named Global Outbreak Lineages (PANGOLIN) [26]. The FASTA files were deposited in the  
114 Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV database [2]. All GISAID  
115 Accession IDs are noted in Table S1.

116

### 117 ***TaqMan assay***

118 We used the pre-designed TaqMan SARS-CoV-2 Mutation Panel for detecting  
119 SARS-CoV-2 spike  $\Delta 69-70$ , G339D and Q493R (Thermo Fisher Scientific). The TaqMan  
120 probe detected both wild-type and variant sequences of SARS-CoV-2, with the TaqMan minor  
121 groove binder probe for the wild-type allele labelled with VIC dye and the variant allele with  
122 FAM dye fluorescence. TaqPath 1-Step RT-qPCR Master Mix CG was used as master mix  
123 and the qPCR was performed on the Step-One Plus Real Time PCR System (Thermo Fisher  
124 Scientific).

125

126 ***Ethics approval***

127 The Institutional Review Board of the Clinical Research and Genome Research  
128 Committee at Yamanashi Central Hospital approved this study and the use of an opt-out  
129 consent method (Approval No. C2019-30). The requirement for written informed consent  
130 was waived owing to the observational nature of this study and the urgent need to collect  
131 COVID-19 data.

132

133 **Results**

134 ***Multiple mutations are present in Omicron***

135 Omicron contains numerous mutations compared with other VOCs [27-29]. Thirty-  
136 three mutations have been identified in the spike protein in BA.1, 34 in BA.1.1 and 29 in BA.2.  
137 BA.1 and BA.1.1 share 33 mutations, but BA.1.1 has an additional mutation in R346K  
138 compared with BA.1 (Figure 1). Compared with BA.1 and BA.1.1, the spike protein mutations  
139 in BA.2 are very different. Unique mutations in BA.1/BA.1.1 are A67V,  $\Delta 69-70$ , T95I,  $\Delta 143-$   
140  $145$ , N211I,  $\Delta 212$ , S371L, G466S, G496S, T547K, N856K and L981F. Conversely, unique  
141 mutations in BA.2 are T19I, L24S,  $\Delta 25-27$ , V213G, S371F, T376A, D405N and R408S.

142

143 ***Construction of a TaqMan assay to distinguish Omicron sublineages***

144 To distinguish BA.1/BA.1.1 from BA.2, we constructed a TaqMan assay system to  
145 analyze the spike protein mutations that characterize the Omicron sublineages. Thus, we  
146 used pre-designed TaqMan probes to distinguish  $\Delta 69-70$ , G339D and Q493R. Spike G339D  
147 and Q493R mutations are detected in BA.1/BA.1.1 and BA.2 but not in other VOCs (Figure  
148 S1). The spike  $\Delta 69-70$  mutation was also used to distinguish sublineages because it is  
149 detected in BA.1/BA.1.1 but not in BA.2 (Figure 1). When analyzed using nucleic acids  
150 extracted from nasopharyngeal swabs, G339D and Q493R mutations were specifically  
151 detected in Omicron-infected patients (Figure 2A and 2B). In addition, the  $\Delta 69-70$  mutation  
152 was distinct between BA1/BA.1.1 and BA.2 (Figure 2C). These results showed that TaqMan  
153 assays could detect Omicron strains and distinguish between Omicron sublineages.

154

155 ***Comparison of TaqMan assay and WGS data***

156 To examine whether the TaqMan assay could accurately distinguish Omicron  
157 sublineages, we compared WGS data and TaqMan assay results using 169 SARS-CoV-2  
158 positive samples (Table 1). WGS analysis determined 127 samples to be BA.1/BA.1.1 and  
159 42 samples to be BA.2 (Table 1). In these samples, TaqMan assay analysis showed that all  
160 BA.1/BA.1.1 samples were positive for  $\Delta 69-70$ , G339D and Q493R, while BA.2 samples  
161 were negative for  $\Delta 69-70$  and positive for G339D and Q493R (Table 1). The TaqMan assay

162 data were consistent with WGS data, demonstrating 100% (169/169) agreement. Therefore,  
163 the TaqMan assay represents a useful technique for distinguishing Omicron sublineages.

164

### 165 ***Mutations in TaqMan assay target sites***

166 During WGS analysis of serially collected samples, SARS-CoV-2 viruses with the  
167 spike G339N mutation (position 22577–22578: c.1015\_1016delGGGinsAA) were detected  
168 in two individuals (Accession ID: EPI\_ISL\_11018144 and EPI\_ISL\_11018145) (Figure 3A).  
169 Analysis with PANGOLIN classified these samples as BA.2. The mutation that occurred at  
170 codon 399 overlapped with the target site of the TaqMan assay. We therefore examined  
171 whether the TaqMan assay targeting G339D could efficiently amplify the target site in the  
172 sample with G339N. In both BA.2 G339D and BA.2 G339N samples, sufficient amplification  
173 signals were obtained for  $\Delta 69-70$  and Q493R. However, compared with BA.2 G339D, BA.2  
174 G339N showed a lower amplification efficiency of the variant allele-specific signal (blue line  
175 in Figure 3B). In conclusion, the TaqMan assay used in this study specifically detected  
176 characteristic mutations related to Omicron sublineages in clinical samples.

177

## 178 **Discussion**

179 In this study, we present data regarding the use of a TaqMan assay to distinguish  
180 between Omicron strains and their sublineages. WGS analysis is the most standard method  
181 to determine these sublineages. However, WGS analysis of all specimens is restricted by  
182 limited resources and is difficult to apply under conditions of rapid spread of infection. In this  
183 regard, we have established a TaqMan assay that more conveniently and rapidly identifies  
184 Omicron strains and distinguishes the sublineages. BA.1/BA.1.1 and BA.2 are reported to  
185 differ in transmissibility and treatment response, and so the World Health Organization  
186 recommends monitoring BA.2 as a separate sublineage [30]. Therefore, assay systems that  
187 distinguish these subtypes will be important in determining preventive measures, infection  
188 control and treatment strategies.

189 Each viral lineage has its own characteristic mutations. By targeting these mutations,  
190 it is possible to distinguish mutant strains and sublineages. Based on the accumulating WGS  
191 data during surveillance, we consider the TaqMan assay to be a suitable approach to detect  
192 characteristic mutations that occur frequently among viral lineages. According to the GISAID  
193 database, as of March 11, 2022, the frequency of mutations targeted in this study detected  
194 in each sublineage were as follows.  $\Delta 69-70$  in 96.1%, 95.7% and 0.1% of BA.1, BA.1.1 and  
195 BA.2, respectively; G339D in 87.9%, 99.3% and 96.3% of BA.1, BA.1.1 and BA.2,  
196 respectively; Q493R in 88.3%, 91.2% and 92% of BA.1, BA.1.1 and BA.2, respectively [29].  
197 It is also possible to target other mutations as reported by other groups [31, 32]. Analysis of

198 multiple characteristic mutations is expected to improve the accuracy of classification of virus  
199 lineage.

200 WGS analysis generally requires labor-intensive procedures such as reverse  
201 transcription reactions from RNA to cDNA, library preparation, purification and library  
202 quantification. In addition, facilities and laboratories with limited analytical equipment and  
203 resources cannot perform WGS analysis. Alternatively, TaqMan assays are useful to  
204 distinguish VOCs and their sublineages quickly and easily in any laboratory with qPCR  
205 facilities. Recently, a Delta-Omicron hybrid strain (AY.4/BA.1 recombinant,  
206 EPI\_ISL\_10819657) was reported in France and has been detected in several European  
207 countries [2, 33]. The TaqMan method could be adapted to identify any such newly emerging  
208 mutant strains.

209 There are, however, several limitations. TaqMan assays do not always accurately  
210 determine the sublineages in some situations. WGS analysis may be necessary when the  
211 characteristic mutations of newly-emerging strains or sublineages remain under investigation.  
212 It should also be noted that if mutations occur at the TaqMan probe or primer locations, the  
213 PCR amplification efficiency will be reduced and the signal will be attenuated, which may  
214 make interpretation difficult (Figure 3B).

215 Our study showed that the TaqMan assay can be used to specifically detect Omicron  
216 viruses and classify subvariants. By applying this method to SARS-CoV-2-positive  
217 specimens, it is possible to analyze multiple specimens rapidly. Although accumulated data  
218 are still needed [8, 11, 14, 34], BA.1 and BA.2 show different susceptibilities to antibody and  
219 antiviral therapy. Rapid classification of Omicron sublineages may be clinically critical in  
220 providing appropriate treatment to patients with COVID-19.

221

## 222 **Data availability**

223 The sequences of SARS-CoV-2 genomes are available on GISAID  
224 ([www.gisaid.org](http://www.gisaid.org)). We have provided the accession numbers in the Supplementary  
225 Information. Source data are provided with this paper.

226

## 227 **Acknowledgements**

228 We thank all medical and ancillary hospital staff for their support. We thank Gillian  
229 Campbell, PhD, from Edanz (<https://www.jp.edanz.com/ac>) for editing a draft of this  
230 manuscript.

231

## 232 **Conflict of interest**

233 The authors have no conflicts of interest.

234

## 235 **Funding source**

236 This study was supported by a Grant-in-Aid for the Genome Research Project from  
237 Yamanashi Prefecture (to M.O. and Y.H.), the Japan Society for the Promotion of Science  
238 (JSPS) KAKENHI Early-Career Scientists JP18K16292 (to Y.H.), a Grant-in-Aid for Scientific  
239 Research (B) 20H03668 (to Y.H.), a Research Grant for Young Scholars (to Y.H.), the  
240 YASUDA Medical Foundation (to Y.H.), the Uehara Memorial Foundation (to Y.H.) and  
241 Medical Research Grants from the Takeda Science Foundation (to Y.H.).

242

## 243 **Reference**

- 244 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L  
245 *et al*: **A pneumonia outbreak associated with a new coronavirus of probable bat**  
246 **origin**. *Nature* 2020, **579**(7798):270-273.
- 247 2. Shu Y, McCauley J: **GISAID: Global initiative on sharing all influenza data - from**  
248 **vision to reality**. *Euro Surveill* 2017, **22**(13).
- 249 3. van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, Owen CJ, Pang J, Tan  
250 CCS, Boshier FAT *et al*: **Emergence of genomic diversity and recurrent mutations in**  
251 **SARS-CoV-2**. *Infection, Genetics and Evolution* 2020, **83**:104351.
- 252 4. Oude Munnink BB, Worp N, Nieuwenhuijse DF, Sikkema RS, Haagmans B, Fouchier  
253 RAM, Koopmans M: **The next phase of SARS-CoV-2 surveillance: real-time**  
254 **molecular epidemiology**. *Nature Medicine* 2021, **27**(9):1518-1524.
- 255 5. World Health Organization: **Classification of Omicron (B.1.1.529): SARS-CoV-2**  
256 **Variant of Concern**. 2021.
- 257 6. Desingu PA, Nagarajan K: **Omicron BA.2 lineage spreads in clusters and is**  
258 **concentrated in Denmark**. *Journal of Medical Virology* 2022.
- 259 7. Fonager J, Bennedbæk M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, Edslev SM,  
260 Stegger M, Sieber RN, Lassauniere R *et al*: **Molecular epidemiology of the SARS-CoV-**  
261 **2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January**  
262 **2022**. *Eurosurveillance* 2022, **27**(10):2200181.
- 263 8. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J,  
264 Shirakawa K *et al*: **Virological characteristics of SARS-CoV-2 BA.2 variant**. *bioRxiv*  
265 2022:2022.2002.2014.480335.
- 266 9. Emma B. Hodcroft: **CoVariants: SARS-CoV-2 Mutations and Variants of Interest**.  
267 2021.
- 268 10. Ito K, Piantham C, Nishiura H: **Estimating relative generation times and relative**  
269 **reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta in Denmark**.



- 270 *medRxiv* 2022:2022.2003.2002.22271767.
- 271 11. Iketani S, Liu L, Guo Y, Liu L, Chan JFW, Huang Y, Wang M, Luo Y, Yu J, Chu H *et al*:  
272 **Antibody evasion properties of SARS-CoV-2 Omicron sublineages.** *Nature* 2022.
- 273 12. Mykytyn AZ, Rissmann M, Kok A, Rosu ME, Schipper D, Breugem TI, van den Doel PB,  
274 Chandler F, Bestebroer T, de Wit M *et al*: **Omicron BA.1 and BA.2 are antigenically**  
275 **distinct SARS-CoV-2 variants.** *bioRxiv* 2022:2022.2002.2023.481644.
- 276 13. Yu J, Collier A-rY, Rowe M, Mardas F, Ventura JD, Wan H, Miller J, Powers O, Chung B,  
277 Siamatu M *et al*: **Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.**  
278 *New England Journal of Medicine* 2022.
- 279 14. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-  
280 Horimoto K, Halfmann P, Watanabe S, Maeda K *et al*: **Efficacy of Antiviral Agents**  
281 **against the SARS-CoV-2 Omicron Subvariant BA.2.** *New England Journal of Medicine*  
282 2022.
- 283 15. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-  
284 Horimoto K, Chiba S, Halfmann P, Nagai H *et al*: **Efficacy of Antibodies and Antiviral**  
285 **Drugs against Covid-19 Omicron Variant.** *New England Journal of Medicine* 2022.
- 286 16. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, Katoh H, Sakata M, Nakatsu Y,  
287 Mori Y *et al*: **Development of Genetic Diagnostic Methods for Novel Coronavirus**  
288 **2019 (nCoV-2019) in Japan.** *Jpn J Infect Dis* 2020, **73**(4):304-307
- 289 17. Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, Sueki H,  
290 Mochizuki H, Tsutsui T, Kakizaki Y *et al*: **Analysis of Covid-19 and non-Covid-19**  
291 **viruses, including influenza viruses, to determine the influence of intensive**  
292 **preventive measures in Japan.** *J Clin Virol* 2020, **129**:104543.
- 293 18. Hirotsu Y, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K, Sueki H, Amemiya  
294 K, Hayakawa M, Mochizuki H *et al*: **Direct comparison of Xpert Xpress, FilmArray**  
295 **Respiratory Panel, Lumipulse antigen test, and RT-qPCR in 165 nasopharyngeal**  
296 **swabs.** *BMC Infectious Diseases* 2022, **22**(1):221.
- 297 19. Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, Sueki H,  
298 Hayakawa M, Mochizuki H, Tsutsui T *et al*: **Prospective Study of 1,308**  
299 **Nasopharyngeal Swabs from 1,033 Patients using the LUMIPULSE SARS-CoV-2**  
300 **Antigen Test: Comparison with RT-qPCR.** *International Journal of Infectious Diseases*  
301 2021.
- 302 20. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, Sueki H,  
303 Hayakawa M, Mochizuki H, Tsutsui T *et al*: **Comparison of Automated SARS-CoV-2**  
304 **Antigen Test for COVID-19 Infection with Quantitative RT-PCR using 313**  
305 **Nasopharyngeal Swabs Including from 7 Serially Followed Patients.** *International*

- 306 *Journal of Infectious Diseases* 2020.
- 307 21. Hirotsu Y, Omata M: **Detection of R.1 lineage severe acute respiratory syndrome**  
308 **coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in**  
309 **Japan.** *PLOS Pathogens* 2021, **17**(6):e1009619.
- 310 22. Hirotsu Y, Omata M: **SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1**  
311 **lineage in Japan: Serial and stationary observation in a community.** *Infection,*  
312 *Genetics and Evolution* 2021, **95**:105088.
- 313 23. Hirotsu Y, Omata M: **Discovery of a SARS-CoV-2 variant from the P.1 lineage**  
314 **harboring K417T/E484K/N501Y mutations in Kofu, Japan.** *Journal of Infection* 2021,  
315 **82**(6):276-316.
- 316 24. Shepard SS, Meno S, Bahl J, Wilson MM, Barnes J, Neuhaus E: **Viral deep sequencing**  
317 **needs an adaptive approach: IRMA, the iterative refinement meta-assembler.** *BMC*  
318 *Genomics* 2016, **17**:708.
- 319 25. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford  
320 T, Neher RA: **Nextstrain: real-time tracking of pathogen evolution.** *Bioinformatics*  
321 2018, **34**(23):4121-4123.
- 322 26. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG:  
323 **A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic**  
324 **epidemiology.** *Nat Microbiol* 2020, **5**(11):1403-1407.
- 325 27. Wang L, Cheng G: **Sequence analysis of the emerging SARS-CoV-2 variant Omicron**  
326 **in South Africa.** *Journal of Medical Virology* 2022, **94**(4):1728-1733.
- 327 28. Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim AS:  
328 **Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern**  
329 **and its global perspective.** *Journal of Medical Virology* 2022, **94**(4):1738-1744.
- 330 29. Julia LM, Ginger T, Alaa AL, Manar A, Marco C, Emily H, Jerry Z, Mark Z, Nate M, Kristian  
331 GA *et al*: **outbreak.info.**
- 332 30. World Health Organization: **Statement on Omicron sublineage BA.2.** 2022.
- 333 31. Erster O, Kabat A, Asraf H, Levy V, Mannasse B, Azar R, Nemet I, Kliker L, Fleishon S,  
334 Mandelboim M *et al*: **Novel RT-qPCR assays enable rapid detection and**  
335 **differentiation between SARS-CoV-2 Omicron (BA.1) and BA.2 variants.** *medRxiv*  
336 2022:2022.2002.2022.22271222.
- 337 32. Lee WL, Gu X, Armas F, Wu F, Chandra F, Chen H, Xiao A, Leifels M, Chua FJD, Kwok  
338 GW *et al*: **Quantitative detection of SARS-CoV-2 Omicron BA.1 and BA.2 variants in**  
339 **wastewater through allele-specific RT-qPCR.** *medRxiv*  
340 2022:2021.2012.2021.21268077.
- 341 33. Colson P, Fournier P-E, Delerce J, Million M, Bedotto M, Houhamdi L, Yahy N, Bayette J,


- 342           Levasseur A, Fantini J *et al*: **Culture and identification of a “Deltamicron” SARS-CoV-**  
343           **2 in a three cases cluster in southern France.** *medRxiv*  
344           2022:2022.2003.2003.22271812.  
345    34.    Zhou H, Tada T, Dcosta BM, Landau NR: **Neutralization of SARS-CoV-2 Omicron BA.2**  
346           **by Therapeutic Monoclonal Antibodies.** *bioRxiv* 2022:2022.2002.2015.480166.  
347  
348

349 **Table 1. Comparison of results between WGS and TaqMan assay**

Lineage	WGS		TaqMan assay	
	n	Spike $\Delta$ 69-70	Spike Q493R	Spike G339D
BA.1 / BA.1.1	127	127	127	127
BA.2	42	0	42	42

350 WGS, whole genome sequencing





359


360

361 **Figure 2. Genotyping of Omicron sublineages by TaqMan assay**

362 (A-C) Samples were analyzed with a TaqMan assay that detects mutations in  
363 Omicron spike proteins. Spike protein mutations G339D (A), Q493R (B) and  $\Delta$ 69–70 (C)  
364 were targeted. G399D and Q493R indicated Omicron (including BA.1/BA.1.1 and BA.2),  
365 while  $\Delta$ 69–70 was used to distinguish BA.1/BA.1.1 from BA.2. Blue circles indicate variant  
366 alleles (FAM dye) and red circles indicate wild-type alleles (VIC dye).

367

(A) Wild type **ACAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCCACC**  
 BA.2 (G339D) **ACAACTTGTGCCCTTTT**GAT**GAAGTTTTTAACGCCACC**  
 BA.2 (G339N) **ACAACTTGTGCCCTTTT**AAT**GAAGTTTTTAACGCCACC**




368

369

370 **Figure 3. Analysis of samples with mutations in the TaqMan probe site**

371 Two samples were classified by WGS analysis as BA.2 containing a G339N  
 372 mutation. (A) The mutation site occurred at codon 339, from wild type (GGT, glycine [G]) to  
 373 the variant form (GAT, aspartate [D] or AAT, aspartate [N]). (B) Most BA.2 lineage viruses  
 374 carry the G339D mutation, but two samples showed a G339N mutation by WGS. Compared  
 375 with BA.2 G339D, the fluorescent signal (blue line) was lower in the BA.2 G339N samples.  
 376



377

378

379 **Figure S1. Mutation frequency in VOCs and Omicron sublineages**

380 The percentages of spike mutations Δ69–70, G339D and Q493R in each VOC analyzed in  
381 this study are shown. The pink circles indicate the presence of mutations. The frequency of  
382 mutation data was referenced from the website outbreak.info [29].